摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-Brom-1-hydroxy-2,2,6,6-tetramethyl-piperidin | 1796-19-6

中文名称
——
中文别名
——
英文名称
4-Brom-1-hydroxy-2,2,6,6-tetramethyl-piperidin
英文别名
4-bromo-2,2,6,6-tetramethyl-piperidin-1-ol;4-Bromo-2,2,6,6-tetramethylpiperidin-1-ol;4-bromo-1-hydroxy-2,2,6,6-tetramethylpiperidine
4-Brom-1-hydroxy-2,2,6,6-tetramethyl-piperidin化学式
CAS
1796-19-6
化学式
C9H18BrNO
mdl
——
分子量
236.152
InChiKey
YYQDYGWDAUVQSL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    23.5
  • 氢给体数:
    1
  • 氢受体数:
    2

文献信息

  • Blends of quinone alkide and nitroxyl compounds and polymerization inhibitors
    申请人:——
    公开号:US20040010159A1
    公开(公告)日:2004-01-15
    Disclosed herein is a method for inhibiting the premature polymerization of ethylenically unsaturated monomers comprising adding to said monomers an effective amount of: A) at least one nitroxyl compound, and B) at least one quinone alkide compound having an electron-withdrawing group at the 7-position. Additionally, a composition is disclosed that comprises: A) at least one nitroxyl compound, and B) at least one quinone alkide compound having an electron-withdrawing group at the 7-position.
    本公开涉及一种抑制乙烯基不饱和单体的过早聚合的方法,包括向所述单体中添加有效量的:A) 至少一种亚硝基化合物,和B) 在7位具有电子吸引基团的至少一种醌烯化合物。此外,还公开了一种包括:A) 至少一种亚硝基化合物,和B) 在7位具有电子吸引基团的至少一种醌烯化合物的组合物。
  • [EN] SULFONATED PHENOLS WITH NITROPHENOLS AS POLYMERIZATION INHIBITORS<br/>[FR] PHENOLS SULFONES AVEC NITROPHENOLS COMME INHIBITEURS DE POLYMERISATION
    申请人:CHEMTURA CORP
    公开号:WO2006036274A1
    公开(公告)日:2006-04-06
    Disclosed herein is a method for inhibiting the premature polymerization and the polymer growth of ethylenically unsaturated monomers comprising adding to said monomers an effective amount of a combination of (A) at least one inhibitor that is a sulfonated phenol of the formula (I): wherein (1) R2 is selected from the group consisting of hydrogen and hydrocarbyl; and (2) R1 and R3 are independently selected from the group consisting of hydrogen and SO3H, provided that at least one of R1 and R3 is SO3H; (B) at least one inhibitor that is a nitrophenol; and, optionally, (C) an inhibitor selected from the group consisting of nitroxyl compounds and nitrosoanilines; and (D) an amine.
    本文公开了一种抑制乙烯基不饱和单体的过早聚合和聚合生长的方法,包括向该单体中添加以下组合物的有效量:(A)至少一种为公式(I)的磺化抑制剂,其中(1)R2选自氢和烃基组成的群体;(2)R1和R3独立地选自氢和SO3H组成的群体,但其中至少一个为SO3H;(B)至少一种为硝基抑制剂;以及可选地,(C)从硝基氧化物化合物和硝基苯胺组成的群体中选择的抑制剂;和(D)胺。
  • HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE
    申请人:Patil Ghanshyam
    公开号:US20080280890A1
    公开(公告)日:2008-11-13
    The present disclosure provides compounds that include hydroxylamines of formula I or II, pharmaceutical compositions, and methods for their use. The methods utilize hydroxylamine compounds and/or their pharmaceutical compositions for the treatment of angiogenesis, hepatitis, complement-mediated pathologies, drusen-mediated pathologies, macular degeneration and certain other ophthalmic conditions, inflammation, arthritis, and related diseases and for the inhibition of complement activation.
    本公开提供了包括式I或II的羟胺化合物、制药组合物以及它们的使用方法。该方法利用羟胺化合物及/或其制药组合物治疗血管生成、肝炎、补体介导的病理、色斑介导的病理、黄斑变性和某些其他眼科疾病、炎症、关节炎和相关疾病,并抑制补体激活。
  • Hydroxylamine compounds and methods of their use
    申请人:Colby Pharmaceutical Company
    公开号:EP2620429A1
    公开(公告)日:2013-07-31
    The present disclosure provides compounds that include hydroxylamines of formula I or II, pharmaceutical compositions, and methods for their use. The methods utilize hydroxylamine compounds and/or their pharmaceutical compositions for the treatment of angiogenesis, hepatitis, complement-mediated pathologies, drusen-mediated pathologies, macular degeneration and certain other ophthalmic conditions, inflammation, arthritis, and related diseases and for the inhibition of complement activation.
    本公开提供了包括式 I 或式 II 的羟胺化合物、药物组合物及其使用方法。这些方法利用羟胺化合物和/或其药物组合物治疗血管生成、肝炎、补体介导的病变、褐斑介导的病变、黄斑变性和某些其他眼科疾病、炎症、关节炎和相关疾病以及抑制补体活化。
  • CURABLE COMPOSITIONS
    申请人:Reichhold LLC 2
    公开号:EP3002312A1
    公开(公告)日:2016-04-06
    The present invention relates generally to accelerators for the curing of thermosetting resins in the presence of metal compounds, quaternary ammonium and/or phosphonium salts, tertiary amines and/or phosphines and peroxide initiators, and methods of curing thermosetting resins using these accelerators.
    本发明一般涉及在属化合物、季盐和/或盐、叔胺和/或膦和过氧化物引发剂存在下固化热固性树脂促进剂,以及使用这些促进剂固化热固性树脂的方法。
查看更多

同类化合物

(R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 ((3S,4R)-3-氨基-4-羟基哌啶-1-基)(2-(1-(环丙基甲基)-1H-吲哚-2-基)-7-甲氧基-1-甲基-1H-苯并[d]咪唑-5-基)甲酮盐酸盐 高氯酸哌啶 高托品酮肟 马来酸帕罗西汀 颜料红48:4 顺式3-氟哌啶-4-醇盐酸盐 顺式2,6-二甲基哌啶-4-酮 顺式1-苄基-4-甲基-3-甲氨基-哌啶 顺式-叔丁基4-羟基-3-甲基哌啶-1-羧酸酯 顺式-6-甲基-哌啶-1,3-二甲酸1-叔丁酯 顺式-5-(三氟甲基)哌啶-3-羧酸甲酯盐酸盐 顺式-4-叔丁基-2-甲基哌啶 顺式-4-Boc-氨基哌啶-3-甲酸甲酯 顺式-4-(氮杂环丁烷-1-基)-3-氟哌 顺式-3-顺式-4-氨基哌啶 顺式-3-甲氧基-4-氨基哌啶 顺式-3-BOC-3,7-二氮杂双环[4.2.0]辛烷 顺式-3-(1-吡咯烷基)环丁腈 顺式-3,5-哌啶二羧酸 顺式-3,4-二溴-3-甲基吡咯烷盐酸盐 顺式-2,6-二甲基-4-氧代哌啶-1-羧酸叔丁基酯 顺式-1-叔丁氧羰基-4-甲基氨基-3-羟基哌啶 顺式-1-boc-3,4-二氨基哌啶 顺式-1-(4-叔丁基环己基)-4-苯基-4-哌啶腈 顺式-1,3-二甲基-4-乙炔基-6-苯基-3,4-哌啶二醇 顺-4-(4-氟苯基)-1-(4-异丙基环己基)-4-哌啶羧酸 顺-4-(2-氟苯基)-1-(4-异丙基环己基)-4-哌啶羧酸 顺-3-氨基-4-氟哌啶-1-羧酸叔丁酯 顺-1-苄基-4-甲基哌啶-3-氨基酸甲酯盐酸盐 非莫西汀 雷芬那辛 雷拉地尔 阿维巴坦中间体4 阿格列汀杂质 阿尼利定盐酸盐 CII 阿尼利定 阿塔匹酮 阿哌沙班杂质BMS-591455 阿哌沙班杂质87 阿哌沙班杂质52 阿哌沙班杂质51 阿哌沙班杂质5 阿哌沙班杂质 阿哌沙班杂质 阿哌沙班-d3 阿哌沙班 阻聚剂701 间氨基谷氨酰胺